Jithma Abeykoon, M.D.

Registration is now open for the 2026 Patient & Family Gathering in Birmingham, Alabama, April 29–30. Join patients, families, and caregivers to connect, learn from experts, and explore the latest research. Reserve your hotel by April 6. erdheim-chester.org/reminder-regis…

Check it out " HPV16 E6 oncoprotein promotes microhomology-mediated viral integration by increasing PolΘ protein expression | PNAS pnas.org/doi/10.1073/pn… @pnas MMEJ is very relevant in the pathobiology of oncogene driven malignancy. More to come!

#letstalkhistiocytosis Join us live on March 18! Registration is open to all us02web.zoom.us/webinar/regist… I couldn’t be more thrilled & honored to share the stage with Dr. Jennifer Picarsic @jpcrsc to discuss the many faces of Histiocytosis diagnostics in clinical practice

@ZanwarSaurabh Phenomenal job

Finally out in press! Multi-institutional cohort of patients with Waldenström macroglobulinemia uniformly treated with bendamustine-rituximab (BR). ⏱ Median follow-up: 5.9 years 🔹 5-year PFS: 65% 🔹 5-year OS: 87% Key highlights: 🌟 CXCR4 mutations identify a subgroup with markedly inferior PFS despite BR 🌟 POD24 is independently associated with inferior overall survival Huge thanks to the amazing collaborators across US and Europe. @JithmaA @MyelomaDrKapoor @VincentRK @Myeloma_mSMART @thanosdimop @ShirleyDSa1 @jonaspaludo ashpublications.org/bloodadvances/…

2/ #3540: High-resolution WES across WM disease states reveals TP53 and MAP3K14 alterations accumulating at relapse. Distinct CNA patterns, including BCL6 gains and strong signal of non-canonical MAPK activity in relapsed WM, define treatment-exposed and high-risk biology. @JithmaA

Mayo Clinic in Rochester has been named the No. 1 smart hospital in the world by Newsweek's "World's Best Smart Hospitals 2026" and earned more No. 1 specialty rankings than any other hospital in the "World's Best Specialized Hospitals 2026" list. More: newsnetwork.mayoclinic.org/discussion/may…

A comprehensive review article on the risk stratification of all plasma cell disorders by @VincentRK @ZanwarSaurabh Myeloma, MGUS, SMM, Amyloid, WM — all here. Open Access. nature.com/articles/s4137…

Very important meeting for patients with histiocytic cancers. Consider attending histiocytesociety.org/HS-2025

🔁 Re-sharing a study from our group on long-term outcomes in adult LCH 🧬 Clinical phenotypes, treatment patterns, and prognostic factors 📊 219 adults | ↑ mortality vs general population esp. among <55y and multi-system disease 🔗 tinyurl.com/yvdry9ms #LCH #RareDiseases

And now into the head and neck region. As expected, Dr. Katharine Price delivers an outstanding presentation on advances in head and neck cancer including KN-689. But who really benefits…? @MayoMedEd @MayoCancerCare @MayoHemeOnc

@lymphoma @LLSusa @AACR Thank you for the opportunity to present our preliminary findings related to this work. Here is the publication.

Our findings are important and open a new understanding of biology and novel way of therapy @MayoCancerCare @WitzigLab JCI - Cyclin D1 overexpression induces replication stress and microhomology-mediated end-joining dependence in mantle cell lymphoma jci.org/articles/view/…

Redefining risk stratification in pLCH sciencedirect.com/science/articl… This is a significant study that redefines risk stratification in pediatric LCH. @ECDGA @HistiocyteSoc @MayoCancerCare

@OhadOrenMDMPH @MayoCancerCare @WitzigLab Thank you so much

@JithmaA @MayoCancerCare @WitzigLab Congratulations, @JithmaA !

Our findings are important and open a new understanding of biology and novel way of therapy @MayoCancerCare @WitzigLab JCI - Cyclin D1 overexpression induces replication stress and microhomology-mediated end-joining dependence in mantle cell lymphoma jci.org/articles/view/…

Hope our findings will help to bring replication stress and MMEJ targeted therapy from bench to bedside not only for MCL but also for other oncogene driven hematologic malignancies @lymphoma @MayoLymphoma @MayoCancerCare @ECDGA @ASHClinicalNews

Replication stress and DNA damage repair pathways have not been well studied in blood cancers. Our findings show that these pathways play a major role in lymphoma biology and can be successfully exploited for therapeutic benefit.

These findings are applicable for oncogene driven cancers and our study will pave the path to bring replication stress and MMEJ targeted therapy from bench to bedside not only for MCL but also for other oncogene driven blood cancers. @AACR @ASHClinicalNews @ECDGA @MayoLymphoma

Replication stress biology and DNA damage repair pathways are under studied in blood cancers. Our findings in @JCI highlight that these pathways are important for lymphoma biology and can be successfully exploited for therapeutic benefit.